Analysts’ Viewpoint
Increase in awareness about asthma treatment is expected to drive the global asthma treatment market size during the forecast period. Participation of several organizations such as the Centers for Disease Control and Prevention’s National Asthma Control Program to increase awareness about asthma and its treatment is estimated to boost market development. Furthermore, asthma camps conducted by the Asthma Society of India are anticipated to augment the industry during the forecast period.
Rise in prevalence of asthma, increase in adoption of combination therapy, and surge in focus on development of smart/digital inhalers are propelling the demand for asthma treatment. Furthermore, several companies are engaging in collaborations and focusing on product innovation, which is likely to increase the demand for asthma medications. For instance, AstraZeneca partnered with the Avillion Company to develop ‘PT027,’ an asthma rescue inhaler.
Asthma is a condition, in which the airways narrow and swell, resulting in extra mucus formation. This can make breathing difficult and cause coughing, a whistling sound, and shortness of breath. Asthma is a minor annoyance for some people. For some, it can be a major issue that disrupts daily activities and could result in a life-threatening asthma attack, which is also called asthma exacerbation.
Symptoms in some people worsen in situations such as exercise-induced asthma, which could be exacerbated by cold and dry air. Irritants in the workplace such as chemical fumes, gases, or dust cause occupational asthma. Airborne allergens such as pollen, mold spores, cockroach waste, or skin and dried saliva shed by pets cause allergy-induced asthma.
Asthma medications include nebulizers and spacers. Nebulizer is preferred for asthma patients. It is a device that can deliver doses of medicines quickly and easily to asthma patients.
Asthma is a major public health issue that affects millions of people across the globe. Genetics or environmental factors, such as microbial exposure, passive smoking, and air pollution, are increasing the disease burden in both adults and children, thereby driving the need for asthma medications.
According to the WHO, asthma affected about 262 million people and 455,000 people succumbed to the disease in 2019. Majority of asthma-related deaths occur in low- and lower-middle-income countries, where underdiagnosis and undertreatment are common.
According to CDC, asthma affects nearly 26 million people in the U.S. The disease is estimated to cost more than US$ 56 Bn annually to the society. Thus, increase in number of asthma patients is projected to drive the demand for treatments for asthma during the forecast period.
Asthma is one of the common lifelong chronic diseases. People are increasingly becoming aware about asthma and its treatment. World Asthma Day is an annual event organized by the Global Initiative for Asthma (GINA) to improve awareness about asthma attack treatment across the world. The entire month of May is designated as National Asthma and Allergy Awareness Month to help manage asthma and educate people to raise awareness and improve lives for all. People are aware of common treatment options for asthma such as pressurized metered dose inhalers and dry powder inhalers.
CDC’s National Asthma Control Program aims to support the people in the U.S. in treating asthma in order to achieve better health and improve the quality of life. The program funds states, school programs, and non-government organizations to help them improve their surveillance of asthma, train healthcare professionals, educate individuals and their families about asthma, and explain asthma to the public.
In terms of treatment, the global asthma treatment market has been bifurcated into long-term asthma control medications and quick-relief (rescue) medications. The long-term asthma control medications segment dominated the industry in 2021. It is the most effective treatment choice for asthma. Inhaled corticosteroids (ICS) are the most potent and effective long-term asthma medications. GlaxoSmithKline plc's ADVAIR DISKUS and AstraZeneca's Symbicort are vital long-term asthma medications that hold major share in the business.
Based on route of administration, the global market has been classified into inhaled, oral, intravenous, and subcutaneous. The inhaled segment held major share in 2021. Inhaled drug therapy is the most preferred asthma attack treatment, as the drug is directly absorbed into the epithelium of the lung.
In terms of distribution channel, the global asthma treatment market has been divided into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment accounted for the largest share in 2021. This can be ascribed to the increase in number of asthma therapeutics being dispensed through retail pharmacies and rise in the number of retail pharmacies in developing countries.
North America accounted for major market share in 2021. This can be ascribed to recent FDA approvals, large number of drugs in pipeline, rise in focus on reducing the number of undiagnosed asthma cases, and availability of early treatment in the region. According to the CDC, in 2017, asthma caused an estimated 1.6 million emergency department (ED) visits and 183,000 hospitalizations in the U.S.
The market in Asia Pacific is expected to expand at a higher CAGR during the forecast period. This can be ascribed to high prevalence of asthma, increase in smoking, and rise in environmental pollution in China and India. According to a study published in the Lung India journal, with an estimated 1.5 crore to 2 crore asthma patients, at least one in every 10 asthma patients globally is from India. Increase in focus on respiratory disease management and rise in awareness about managing asthma are fueling market expansion in the region.
The global asthma treatment market is consolidated, with the presence of a small number of large companies. Expansion of product portfolio and mergers & acquisitions are the major strategies adopted by the key players. Leading players in the business are Mylan N.V, AstraZeneca plc., Boehringer Ingelheim, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Lupin Pharmaceuticals, Glenmark Pharmaceuticals, Merck & Co. Inc., Novartis International AG, Sanofi, Sunovion Pharmaceuticals, Inc., and Teva Pharmaceutical Industries.
Leading players have been profiled in the market report based on parameters such as company overview, financial overview, strategies, portfolio, segments, and recent developments.
|
Attribute |
Detail |
|
Size in 2021 |
US$ 24.0 Bn |
|
Forecast (Value) in 2031 |
More than US$ 34.5 Bn |
|
Growth Rate (CAGR) |
3.7% |
|
Forecast Period |
2022–2031 |
|
Historical Data Available for |
2017–2020 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
It was valued at US$ 24.0 Bn in 2021
The industry is projected to reach more than US$ 34.5 Bn by 2031.
The CAGR stood at 3.2% from 2017 to 2021
The market is anticipated to grow at a CAGR of 3.7% from 2022 to 2031
Increase in adoption of combination therapy and rise in prevalence of asthma
North America is expected to account for the largest share
Mylan N.V, AstraZeneca plc., Boehringer Ingelheim, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc., Lupin Pharmaceuticals, Glenmark Pharmaceuticals, Merck & Co. Inc., Novartis International AG, Sanofi, Sunovion Pharmaceuticals, Inc., and Teva Pharmaceutical Industries
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Asthma Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Asthma Treatment Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Bn)
5. Key Insights
5.1. Key Industry Events (Mergers & Acquisitions, Treatment Type Launches, Partnerships, etc.)
5.2. Pipeline Analysis
5.3. Regulatory Scenario by Region/Globally
5.4. COVID-19 Pandemic Impact on the Industry
6. Global Asthma Treatment Market Analysis and Forecast, by Treatment Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Treatment Type, 2017–2031
6.3.1. Long-term Asthma Control Medications
6.3.2. Quick-relief (Rescue) Medications
6.4. Market Attractiveness Analysis, by Treatment Type
7. Global Asthma Treatment Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Route of Administration, 2017–2031
7.3.1. Inhaled
7.3.2. Oral
7.3.3. Intravenous
7.3.4. Subcutaneous
7.4. Market Attractiveness Analysis, by Route of Administration
8. Global Asthma Treatment Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Retail Pharmacies
8.3.2. Hospital Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Asthma Treatment Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Asthma Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Treatment Type, 2017–2031
10.2.1. Long-term Asthma Control Medications
10.2.2. Quick-relief (Rescue) Medications
10.3. Market Value Forecast, by Route of Administration, 2017–2031
10.3.1. Inhaled
10.3.2. Oral
10.3.3. Intravenous
10.3.4. Subcutaneous
10.4. Market Value Forecast, by Distribution Channel, 2017–2031
10.4.1. Retail Pharmacies
10.4.2. Hospital Pharmacies
10.4.3. Online Pharmacies
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Treatment Type
10.6.2. By Route of Administration
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Asthma Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Treatment Type, 2017–2031
11.2.1. Long-term Asthma Control Medications
11.2.2. Quick-relief (Rescue) Medications
11.3. Market Value Forecast, by Route of Administration, 2017–2031
11.3.1. Inhaled
11.3.2. Oral
11.3.3. Intravenous
11.3.4. Subcutaneous
11.4. Market Value Forecast, by Distribution Channel, 2017–2031
11.4.1. Retail Pharmacies
11.4.2. Hospital Pharmacies
11.4.3. Online Pharmacies
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Treatment Type
11.6.2. By Route of Administration
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Asthma Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Treatment Type, 2017–2031
12.2.1. Long-term Asthma Control Medications
12.2.2. Quick-relief (Rescue) Medications
12.3. Market Value Forecast, by Route of Administration, 2017–2031
12.3.1. Inhaled
12.3.2. Oral
12.3.3. Intravenous
12.3.4. Subcutaneous
12.4. Market Value Forecast, by Distribution Channel, 2017–2031
12.4.1. Retail Pharmacies
12.4.2. Hospital Pharmacies
12.4.3. Online Pharmacies
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Treatment Type
12.6.2. By Route of Administration
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Asthma Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Treatment Type, 2017–2031
13.2.1. Long-term Asthma Control Medications
13.2.2. Quick-relief (Rescue) Medications
13.3. Market Value Forecast, by Route of Administration, 2017–2031
13.3.1. Inhaled
13.3.2. Oral
13.3.3. Intravenous
13.3.4. Subcutaneous
13.4. Market Value Forecast, by Distribution Channel, 2017–2031
13.4.1. Retail Pharmacies
13.4.2. Hospital Pharmacies
13.4.3. Online Pharmacies
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Treatment Type
13.6.2. By Route of Administration
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Asthma Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Treatment Type, 2017–2031
14.2.1. Long-term Asthma Control Medications
14.2.2. Quick-relief (Rescue) Medications
14.3. Market Value Forecast, by Route of Administration, 2017–2031
14.3.1. Inhaled
14.3.2. Oral
14.3.3. Intravenous
14.3.4. Subcutaneous
14.4. Market Value Forecast, by Distribution Channel, 2017–2031
14.4.1. Retail Pharmacies
14.4.2. Hospital Pharmacies
14.4.3. Online Pharmacies
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Treatment Type
14.6.2. By Route of Administration
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Market Share/Ranking Analysis, by Company (2021)
15.3. Company Profiles
15.3.1. Mylan N.V.
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Strategic Overview
15.3.2. AstraZeneca plc
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Strategic Overview
15.3.3. Boehringer Ingelheim
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Strategic Overview
15.3.4. F. Hoffmann-La Roche Ltd.
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Strategic Overview
15.3.5. GlaxoSmithKline plc.
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Strategic Overview
15.3.6. Glenmark Pharmaceuticals
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Strategic Overview
15.3.7. Lupin Pharmaceuticals
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Strategic Overview
15.3.8. Merck & Co. Inc.
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Strategic Overview
15.3.9. Novartis International AG
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Strategic Overview
15.3.10. Sanofi
15.3.10.1. Company Overview
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Strategic Overview
15.3.11. Sunovion Pharmaceuticals, Inc.
15.3.11.1. Company Overview
15.3.11.2. Product Portfolio
15.3.11.3. SWOT Analysis
15.3.11.4. Strategic Overview
15.3.12. Teva Pharmaceutical Industries
15.3.12.1. Company Overview
15.3.12.2. Product Portfolio
15.3.12.3. SWOT Analysis
15.3.12.4. Strategic Overview
List of Tables
Table 01: Global Asthma Treatment Market Value (US$ Bn) Forecast, by Treatment Type, 2017‒2031
Table 02: Global Asthma Treatment Market Value (US$ Bn) Forecast, by 2017‒2031, by Route of Administration
Table 03: Global Asthma Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2031
Table 04: Global Asthma Treatment Market Value (US$ Bn) Forecast, by Region, 2017–2031
Table 05: North America Asthma Treatment Market Value (US$ Bn) Forecast, by Country, 2017–2031
Table 06: North America Asthma Treatment Market Value (US$ Bn) Forecast, by Treatment Type, 2017‒2031
Table 07: North America Asthma Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017‒2031
Table 08: North America Asthma Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2031
Table 09: Europe Asthma Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Europe Asthma Treatment Market Value (US$ Bn) Forecast, by Treatment Type, 2017‒2031
Table 11: Europe Asthma Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017‒2031
Table 12: Europe Asthma Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2031
Table 13: Asia Pacific Asthma Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Asia Pacific Asthma Treatment Market Value (US$ Bn) Forecast, by Treatment Type, 2017‒2031
Table 15: Asia Pacific Asthma Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017‒2031
Table 16: Asia Pacific Asthma Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2031
Table 17: Latin America Asthma Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
Table 18: Latin America Asthma Treatment Market Value (US$ Bn) Forecast, by Treatment Type, 2017‒2031
Table 19: Latin America Asthma Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017‒2031
Table 20: Latin America Asthma Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2031
Table 21: Middle East & Africa Asthma Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
Table 22: Middle East & Africa Asthma Treatment Market Value (US$ Bn) Forecast, by Treatment Type, 2017‒2031
Table 23: Middle East & Africa Asthma Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017‒2031
Table 24: Middle East & Africa Asthma Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2031
List of Figures
Figure 01: Global Asthma Treatment Market Value (US$ Bn) Forecast, 2017–2031
Figure 02: Global Asthma Treatment Market Value Share, by Treatment Type, 2021
Figure 03: Global Asthma Treatment Market Value Share, by Route of Administration, 2021
Figure 04: Global Asthma Treatment Market Value Share, by Distribution Channel, 2021
Figure 05: Global Asthma Treatment Market Value Share Analysis, by Treatment Type, 2021 and 2031
Figure 06: Global Asthma Treatment Market Attractiveness Analysis, by Treatment Type, 2022–2031
Figure 07: Global Asthma Treatment Market Value Share Analysis, by Route of Administration, 2021 and 2031
Figure 08: Global Asthma Treatment Market Attractiveness Analysis, by Route of Administration, 2022–2031
Figure 09: Global Asthma Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 10: Global Asthma Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 11: Global Asthma Treatment Market Value Share Analysis, by Region, 2021 and 2031
Figure 12: Global Asthma Treatment Market Attractiveness Analysis, by Region, 2022–2031
Figure 13: North America Asthma Treatment Market Value (US$ Bn) Forecast, 2017–2031
Figure 14: North America Asthma Treatment Market Value Share Analysis, by Country, 2021 and 2031
Figure 15: North America Asthma Treatment Market Attractiveness Analysis, by Country, 2022–2031
Figure 16: North America Asthma Treatment Market Value Share Analysis, by Treatment Type, 2021 and 2031
Figure 17: North America Asthma Treatment Market Attractiveness Analysis, by Treatment Type, 2022–2031
Figure 18: North America Asthma Treatment Market Value Share Analysis, by Route of Administration, 2021 and 2031
Figure 19: North America Asthma Treatment Market Attractiveness Analysis, by Route of Administration, 2022–2031
Figure 20: North America Asthma Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 21: North America Asthma Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 22: Europe Asthma Treatment Market Value (US$ Bn) Forecast, 2017–2031
Figure 23: Europe Asthma Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 24: Europe Asthma Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 25: Europe Asthma Treatment Market Value Share Analysis, by Treatment Type, 2021 and 2031
Figure 26: Europe Asthma Treatment Market Attractiveness Analysis, by Treatment Type, 2022–2031
Figure 27: Europe Asthma Treatment Market Value Share Analysis, by Route of Administration, 2021 and 2031
Figure 28: Europe Asthma Treatment Market Attractiveness Analysis, by Route of Administration, 2022–2031
Figure 29: Europe Asthma Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 30: Europe Asthma Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 31: Asia Pacific Asthma Treatment Market Value (US$ Bn) Forecast, 2017–2031
Figure 32: Asia Pacific Asthma Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 33: Asia Pacific Asthma Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 34: Asia Pacific Asthma Treatment Market Value Share Analysis, by Treatment Type, 2021 and 2031
Figure 35: Asia Pacific Asthma Treatment Market Attractiveness Analysis, by Treatment Type, 2022–2031
Figure 36: Asia Pacific Asthma Treatment Market Value Share Analysis, by Route of Administration, 2021 and 2031
Figure 37: Asia Pacific Asthma Treatment Market Attractiveness Analysis, by Route of Administration, 2022–2031
Figure 38: Asia Pacific Asthma Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 39: Asia Pacific Asthma Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 40: Latin America Asthma Treatment Market Value (US$ Bn) Forecast, 2017–2031
Figure 41: Latin America Asthma Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 42: Latin America Asthma Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021-2031
Figure 43: Latin America Asthma Treatment Market Value Share Analysis, by Treatment Type, 2021 and 2031
Figure 44: Latin America Asthma Treatment Market Attractiveness Analysis, by Treatment Type, 2022–2031
Figure 45: Latin America Asthma Treatment Market Value Share Analysis, by Route of Administration, 2021 and 2031
Figure 46: Latin America Asthma Treatment Market Attractiveness Analysis, by Route of Administration, 2022–2031
Figure 47: Latin America Asthma Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 48: Latin America Asthma Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 49: Middle East & Africa Asthma Treatment Market Value (US$ Bn) Forecast, 2017–2031
Figure 50: Middle East & Africa Asthma Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 51: Middle East & Africa Asthma Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021-2031
Figure 52: Middle East & Africa Asthma Treatment Market Value Share Analysis, by Treatment Type, 2021 and 2031
Figure 53: Middle East & Africa Asthma Treatment Market Attractiveness Analysis, by Treatment Type, 2022–2031
Figure 54: Middle East & Africa Asthma Treatment Market Value Share Analysis, by Route of Administration, 2021 and 2031
Figure 55: Middle East & Africa Asthma Treatment Market Attractiveness Analysis, by Route of Administration, 2022–2031
Figure 56: Middle East & Africa Asthma Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 57: Middle East & Africa Asthma Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 58: Company Share Analysis, 2021
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Asthma Treatment Market
